PUBLISHER: The Business Research Company | PRODUCT CODE: 1942557
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942557
Chemiluminescence immunoassay (CLIA) analyzers are sophisticated laboratory instruments used to detect and measure various substances such as proteins, hormones, and drugs in samples, employing chemiluminescence and immunoassay techniques. They are extensively utilized in clinical laboratories for their precise and automated detection capabilities, particularly for high-sensitivity detection of hormones, proteins, antibodies, and infectious agents.
The main types of CLIA analyzers include fully automated and semi-automated models. Fully automated CLIA analyzers are advanced devices that utilize chemiluminescence to automatically measure and analyze specific molecules in biological samples with high sensitivity and accuracy. They employ technologies such as sequential injection, random access, and batch analysis. These analyzers find applications in oncology, endocrinology, hepatitis and retroviruses, cardiac markers, infectious diseases, bone and mineral disorders, autoimmune diseases, allergies, gastrointestinal (GI) stool testing, and drug discovery and development. They are used by hospitals, clinics, medical laboratories, and pharmaceutical companies.
Tariffs are impacting the chemiluminescence immunoassay analyzer market by increasing costs for imported electronic components, optical systems, reagents, and precision manufacturing equipment used in analyzer production. These cost pressures have particularly affected fully automated and high-throughput analyzer segments, with asia-pacific and europe experiencing higher exposure due to globalized supply chains. Increased tariffs have raised capital equipment prices for hospitals and diagnostic laboratories and slowed procurement cycles. However, tariffs have also encouraged local manufacturing, regional assembly, and sourcing diversification, supporting long-term supply chain resilience.
The chemiluminescence immunoassay analyzer market research report is one of a series of new reports from The Business Research Company that provides chemiluminescence immunoassay analyzer market statistics, including chemiluminescence immunoassay analyzer industry global market size, regional shares, competitors with a chemiluminescence immunoassay analyzer market share, detailed chemiluminescence immunoassay analyzer market segments, market trends and opportunities, and any further data you may need to thrive in the chemiluminescence immunoassay analyzer industry. This chemiluminescence immunoassay analyzer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chemiluminescence immunoassay analyzer market size has grown strongly in recent years. It will grow from $6.03 billion in 2025 to $6.44 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to growth in clinical diagnostic testing volumes, increasing prevalence of infectious diseases, rising demand for accurate hormone testing, expansion of hospital laboratory infrastructure, growing adoption of automated laboratory systems.
The chemiluminescence immunoassay analyzer market size is expected to see strong growth in the next few years. It will grow to $8.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to rising burden of chronic and autoimmune diseases, increasing demand for early disease detection, expansion of diagnostic testing in emerging markets, growing focus on laboratory workflow efficiency, rising adoption of point-of-care immunoassay solutions. Major trends in the forecast period include rising demand for high-sensitivity diagnostic testing, increasing adoption of fully automated immunoassay systems, growing use of CLIA analyzers in infectious disease testing, expansion of CLIA applications in oncology and endocrinology, increasing preference for high-throughput laboratory analyzers.
The increasing prevalence of chronic diseases is expected to drive growth in the chemiluminescence immunoassay analyzer market in the coming years. Factors contributing to this rise include aging populations, unhealthy lifestyles, and advancements in medical care that extend the lifespan of individuals with acute conditions, thereby increasing the incidence of long-term health issues. Chemiluminescence immunoassay analyzers play a crucial role in managing chronic diseases by providing precise and sensitive detection of biomarkers, aiding in accurate diagnosis and monitoring of treatment effectiveness. For example, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, in 2023 approximately 194 million adults in the United States, or 76.4%, reported having at least one chronic condition. The prevalence stood at 59.5% among young adults, increased to 78.4% among midlife adults, and reached 93.0% among older adults. Therefore, the rising prevalence of chronic diseases is driving the growth of the chemiluminescence immunoassay analyzer market.
Leading companies in the chemiluminescence immunoassay analyzer market are focusing on developing advanced diagnostic technologies, such as automated analyzers, to enhance decision-making and analytical capabilities. Automated analyzers perform analytical processes automatically and are widely used in medical laboratories for efficient and accurate testing of samples. For instance, in July 2023, Fapon Biotech Inc., a China-based life sciences company, introduced the Shine i8000/9000 chemiluminescence immunoassay system. This high-speed, fully automated analyzer operates at an ultra-high throughput of 900 tests per hour, enabling partners to develop cutting-edge clinical diagnostic solutions. With initial results available in just 10 minutes, the system provides rapid insights crucial for time-sensitive situations. It boasts a rapid testing pace and high throughput capacity, efficiently managing large sample volumes while maintaining reliable accuracy, making it ideal for medium- to large-scale laboratories.
In November 2023, LASCCO, a Switzerland-based biotechnology company, and Abionic SA, also based in Switzerland, entered into a licensing agreement with Fapon, granting the company the rights to develop and commercialize the PSP (point-of-sample testing) technology. As part of the agreement, Fapon will integrate the PSP technology into its chemiluminescent immunoassay (CLIA) analyzer, with a focus on the Chinese market. Fapon Biotech is a China-based provider of comprehensive solutions in the in vitro diagnostics (IVD) industry.
Major companies operating in the chemiluminescence immunoassay analyzer market are F. Hoffmann-La Roche AG, Abbott Laboratories Inc., Siemens Healthineers AG, Wiener Lab Group, PerkinElmer Inc., BioMerieux SA, Beckman Coulter Life Sciences, Tosoh Bioscience LLC, Bio-Rad Laboratories Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., DiaSorin SpA, Euroimmun AG, Autobio Diagnostics Co. Ltd., Maccura Biotechnology Co. Ltd., Luminex Corporation, Fujirebio Holdings Inc., Randox Laboratories Ltd., Shenzhen Yhlo Biotech Co. Ltd., Addcare Bio-Tech Co. Ltd., Inova Diagnostics, Immunodiagnostic Systems Holdings (IDS), Dynex Technologies Inc., Nanjing Poclight Biotechnology Co. Ltd.
North America was the largest region in the chemiluminescence immunoassay analyzers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemiluminescence immunoassay analyzer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the chemiluminescence immunoassay analyzer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The chemiluminescence immunoassay analyzer market consists of sales of pacifier thermometers, automated instrumentation, quality control materials, and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chemiluminescence Immunoassay Analyzer Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses chemiluminescence immunoassay analyzer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for chemiluminescence immunoassay analyzer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chemiluminescence immunoassay analyzer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.